Novartis gets U.S. priority review for Kymriah for adults with lymphoma

ZURICH (Reuters) - Novartis has been ‍granted priority review for its cell therapy Kymriah for adults with a form of lymphoma by the U.S. Food and Drug Administration, the Swiss drugmaker said on Wednesday, as it seeks to expand use of the treatment in multiple blood cancers.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news